TVG has established a pipeline of animal vaccines and biotherapeutics to address diseases in animals that have serious commercial impact on livestock production or address major unmet needs in companion animal health.
We have a global network of collaborators and have received funding through a combination of commercial development contracts and grant sponsors, including the UK and US governments.
Overview of TVG’s current R&D pipeline.
BRSV: Immunogenicity and efficacy demonstrated in MDA-positive calves
LSDV: Immunogenicity demonstrated in calves
S. suis: Cross-serotype protection demonstrated in piglets, superior to commercial vaccine
ASFV: Immunogenicity demonstrated in pigs.
PRRSV: Immunogenicity (T-cells) and prevention of lung disease demonstrated in pigs.
Lead cattle programme, developed with the Pirbright Institute and supported by Innovate UK.
Lead swine programme, supported by Innovate UK and international funding, with commercial collaboration.
Supported by Innovate UK.
Supported by BBSRC in collaboration with the Pirbright Institute.
Developed with the Pirbright Institute and industry support.
Supported by commercial animal health partner.
Internal companion animal programme.
Internal preclinical programme.
Internal companion animal programme.
Internal equine programme.
Internal preclinical programme.
Internal programme with commercial partner support.
Internal programme with commercial partner input.